Boehringer Ingelheim, a prominent research-driven biopharmaceutical company, in partnership with the Dubai Health Authority (DHA), has achieved a Guinness World Record for creating the ‘Largest light mosaic (image)’. This monumental mosaic was assembled at Dubai Festival City Mall on November 16, illuminating the intricate connections between cardiovascular, renal, and metabolic (CRM) diseases. The event, themed ‘Illuminating Connections, Inspiring Hope’, aimed to raise awareness about the vital need for early diagnosis and comprehensive management of CRM diseases, fostering hope for a brighter future for those affected.
Over one billion people worldwide suffer from CRM diseases, which encompass heart failure, chronic kidney disease, and type 2 diabetes. These diseases are interconnected, often co-existing and exacerbating each other, imposing a substantial burden on patients' lives. This interconnectivity was visually depicted through a vibrant mosaic constructed entirely from energy-efficient LED light bulbs, symbolizing the heart, kidneys, and pancreas linked together.
Enhancing care for CRM diseases was a focal point of the initiative. DHA health educators were present to disseminate information on the risk factors associated with these diseases and to underscore the significance of early detection and holistic management. The public was encouraged to stay informed and consult their doctors if they had any concerns. Participants who engaged with DHA health educators were invited to contribute to the record-breaking mosaic by adding a light bulb, symbolizing their newfound hope and awareness.
Celebrity Kris Fade also participated in the event to amplify these crucial messages. Each bulb added to the mosaic embodied hope and served as a reminder of the transformative power of scientific advancements. Derek O’Leary, regional managing director at Boehringer Ingelheim for the India, Middle East, Turkey, and Africa (IMETA) region, stated: “At Boehringer Ingelheim, we are dedicated to alleviating the burden of CRM diseases in the UAE and the broader region. Beyond innovating to develop breakthrough therapies, we prioritize collaborative efforts to enhance the lives of patients living with CRM diseases. We are honored to collaborate with the DHA and anticipate the positive impact our combined efforts will have on the communities we serve. This public engagement initiative reflects our commitment to transforming lives for generations.”
Dr Mohamed Meshref, medical director at Boehringer Ingelheim for the IMETA region, added: “With our enhanced understanding of the interconnected nature of CRM diseases, it is essential to raise awareness about their associated risk factors. By addressing CRM diseases early and holistically, we can safeguard patients from severe complications and slow disease progression. Furthermore, patients should recognize that adopting healthy eating habits, engaging in regular exercise, and managing stress effectively can significantly improve their overall well-being.”
As a leading biopharmaceutical company, Boehringer Ingelheim remains steadfast in its commitment to delivering value through innovation to patients living with CRM diseases. By advancing life and spearheading the science that leads to breakthrough therapies, Boehringer Ingelheim is dedicated to transforming lives for generations to come.
Source link: https://www.khaleejtimes.com
